摘要
胰腺癌是癌症相关死亡的第4大原因,多数患者初诊时已为局部进展期或出现远处转移,失去手术机会。转化治疗旨在通过综合治疗,使不可切除的肿瘤获得接受根治性手术治疗的机会。在不可切除的胰腺癌中,以AG(白蛋白紫杉醇+吉西他滨)或FOLFIRINOX(5-氟尿嘧啶+亚叶酸+伊立替康+奥沙利铂)方案为基础的化疗及放疗结合化疗等方案显示出转化潜力,靶向治疗和免疫治疗也成为胰腺癌转化治疗的新方向。本文总结了转化治疗的新药物和新方案,综述了胰腺癌转化治疗的最新研究进展。
Pancreatic cancer is the fourth leading cause of cancer-related death in the world.Most patients are diagnosed as locally advanced or metastatic disease at initial visit,losing the opportunity of surgery.Conversion therapy aims to give unresectable tumors the opportunity to receive radical surgery through comprehensive treatment.For unresectable pancreatic cancer,chemotherapy based on AG(abraxane+gemcitabine)or FOLFIRINOX(5-fluorouracil+leucovorin+irinotecan+oxaliplatin),radiotherapy combined with chemotherapy as well as other regimens have shown conversion potential.Targeted therapy and immunotherapy have also become new frontiers of conversion therapy for pancreatic cancer.Focusing on new drugs and new regimens,this review has summarized the latest research progress of conversion therapy for pancreatic cancer.
作者
王雨昕
马永蔌
李宝毅
田孝东
杨尹默
WANG Yuxin;MA Yongsu;LI Baoyi;TIAN Xiaodong;YANG Yinmo(Department of Hepatobiliary Pancreatic Surgery,Peking University First Hospital,Beijing 100034,China)
出处
《肿瘤》
CAS
北大核心
2023年第6期552-558,共7页
Tumor
基金
国家自然科学基金(82171722,82271764,81871954)
北京市自然科学基金(7212111)
关键词
胰腺癌
转化治疗
化疗
放疗
靶向治疗
免疫治疗
Pancreatic cancer
Conversion therapy
Chemotherapy
Radiotherapy
Targeted therapy
Immunotherapy
